which Eli Lilly posted will take effect in the fourth quarter for Humalog and Humulin, its two biggest-selling insulin products. Apart from this move, the manufacturer stated that as of May 1st it will reduce the list price of an unbranded insulin it sells from $82 to $25 a vial.
It will be interesting to observe whether other insulin-manufacturing companies will follow suit with price reductions. They may have to, as otherwise they could lose a considerable amount of their market share. In addition, it will be intriguing to note how payers and PBMs respond.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: